June 6, 2013
The Japan College of Rheumatology issued on June 3 usage guidelines for Pfizer Japan’s new oral rheumatoid arthritis (RA) treatment Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor, to promote the drugs’ appropriate use during post-marketing surveillance (PMS) since the drug...read more